Parallel Advisors’s Filana Therapeutics FLNA Stock Holding History

Parallel Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$290	Hold	244	–	–	﹤0.01%	3837
2026 Q1	$412	Hold	244	–	–	﹤0.01%	3700
2025 Q4	$483	Hold	244	–	–	﹤0.01%	3415
2025 Q3	$710	Hold	244	–	–	﹤0.01%	3286
2025 Q2	$442	Hold	244	–	–	﹤0.01%	3318
2025 Q1	$366	Hold	244	–	–	﹤0.01%	3288
2024 Q4	$576	Hold	244	–	–	﹤0.01%	3198
2024 Q3	$7.18K	Hold	244	–	–	﹤0.01%	2506
2024 Q2	$3.01K	Sell	244 -10	-4%	-$211	﹤0.01%	2681
2024 Q1	$5.15K	Hold	254	–	–	﹤0.01%	2519
2023 Q4	$5.72K	Buy	254 +244	+2,440%	+$5.16K	﹤0.01%	2482
2023 Q3	$166	Hold	10	–	–	﹤0.01%	3251
2023 Q2	$245	Sell	10 -23	-70%	-$554	﹤0.01%	3217
2023 Q1	$796	Buy	33 +23	+230%	+$637	﹤0.01%	3008
2022 Q4	$295	Hold	10	–	–	﹤0.01%	3126
2022 Q3	$0	Hold	10	–	–	﹤0.01%	3453
2022 Q2	$0	Hold	10	–	–	﹤0.01%	3312
2022 Q1	$0	Sell	10 -2	-17%	-$85	﹤0.01%	3242
2021 Q4	$1K	Sell	12 -8	-40%	-$420	﹤0.01%	2948
2021 Q3	$1K	Hold	20	–	–	﹤0.01%	2948
2021 Q2	$2K	Buy	20 +10	+100%	+$536	﹤0.01%	2604
2021 Q1	$0	Buy	+10	New	+$393	﹤0.01%	2886

Other funds holding FLNA

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Parallel Advisors's FLNA Position: Q2 2026 in Review

Parallel Advisors held its Filana Therapeutics (FLNA) position steady in Q2 2026 at 244 shares worth $290. The position accounts for ﹤0.01% of the portfolio, ranked #3837.

Parallel Advisors first reported a position in FLNA in Q1 2021 and has held it in 22 quarters since. The position peaked at $7.18K in Q3 2024. 85 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

Parallel Advisors held 244 shares of Filana Therapeutics worth $290 as of Q2 2026.
Parallel Advisors left its Filana Therapeutics share count unchanged in Q2 2026.
Filana Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3837 holding.
Parallel Advisors first reported a position in Filana Therapeutics in Q1 2021 and has held it in 22 quarters since.
Parallel Advisors's Filana Therapeutics position peaked at $7.18K in Q3 2024.
85 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.